good Thanks, call. the Right. afternoon, for and joining everybody. Thanks Ami,
will We’re the an we’ve of up going lastly, additional give progress how our you provide today’s facets on update XXXX. our call to XXXX. a color ended to on we and We’ll focus all be for expectations of made – also have business, point to some across significant
$XX with bottle our to start franchise So me the amounted our saw for release, net just let shy you million earnings of revenue XXXX about as basis. or $XXX in full year per a headlines, on
exceeded ultimately, that, Our million, future guidance as of of net bode of $XX as revenue to result well. $XX for a performance a performance very million our few well the high-end the factors
management operating activities performance used reflecting its shy million, cash strong Our another as amounted growth year. in expenses net to a equivalents yielded entered meaningful liquidity cash in our investment giving just we that balance, of line and with us so yet million, $XXX of cash, $XXX and expectations year-ending
very net is $XXX XXXX it’s guiding in XXXX we’re there such revenue significant guidance, I At to to million. this range interest the know point, million $XXX in our of for and
XXXX to in XXXX $XXX $XXX advised the of in for of cash as of expenses maintaining revenue operations have guidance levels past. growth year net from you consistent we full Our reflects used million while million to continued XXXX
by in you’re early I’m we to November gave managed focused sure so revenue you big how exceed The question we much. net the relates to guidance on
of our performance that the ended also to end As given and we remember, of we reaching bottom you an $XX million, range. earlier million had guidance $XX up obviously,
hand experience along, to the QX-end, the were of balance that of our said within inventories the year, consistent days volumes as on recognizing, the X wholesale end as did we was have year. all each than have from the effect that now remained months unpredictable last right that of than fairly expected the of year there you days stronger channel other. QX-end We tell our in is more I’ll no meaning
also coupon by patients lower-than-expected card plans. commercial We saw for co-pay utilization covered
The that, quarters we’ve than seen time X co-pay a so row card where lower expected we’ve second it’s than in had utilization.
affordable gap. XX% much continue we of our use less, impact coverage are coupons since the already formulary franchise, largest commercial for driver our revenues was single of the of see Part D higher patients at With coverage or levels. to The co-pays net better Medicare
on benefit an know, is the Part you annual cycle. Medicare As D
starts From and government perspective, pharma, then XX% funded, coverage coverage catastrophic funded. initial then gap a is a enters is deductible, coverage is enters a funded that by ultimately, with it patients’ the phase phase government that that
received or we little invoice for companies and lower was as pharmaceutical it gap. to or much fourth weeks other that to from coverage when We entering our had portion a have our the It no expected. coverage patients the CMS, important is are quarter And ago. note on few information we exiting than
have all assuming patient continuum CMS when level by is the in on get X the quarters changes actual the is our through will we based We exposure future, first learned the effect determined now on insight the of us the XXXX the invoice. there care, of year gap is further better no all how drugs having the invoice, full taking. of It being a of coverage law. in about materialize carrying we
coverage increasing estimates coverage of revenue XXXX. gap will $XXX The net start now from gap best initial range the for this coverage XXXX for our current will phase what Our exposure about the be reflects in size Complicating is is XXXX. higher. guidance the somewhat
the by at of and almost coverage is $X,XXX, for the the pharma then increasing And widening exposure so that end gap – level. fund XX% to
included donut increases elements in in the accounts, throughout Other at to include another now our kicks $X,XXX and the and potential guidance past, hole growth, up of minor XXXX. at used Said penetration catastrophic coverage it’s in moving to in coveraged start volume $X,XXX $X,XXX, way, $X,XXX. now versus, increased
Increased year to believe full XXXX. of penetration in on below price the assume downward drop it’s $XX do revenue that XXXX. that safe the pricing, pressure per net per net the $XXX heels We puts not for on but of will bottle bottle that
Changing Mitro insights, to for it further gears over touch briefly I like Tom we other our in commercial before that have to I’d turn initiatives on important company.
clinical Our we our this XXXX. of retina for from as number of dexamethasone our by continue. sustained is insert end Phase data for release And expect Remember, programs trial now the AR-XXXX top-line a conditions. retinal X
to in of acquisition the Also, enrollment the human XXXX in Xb of In second to first X addition, study later we for expect Avizorex our commence we half continue be year. clinical our dry-eye powered AR-XXXXX the trial be we’ll product which trial, Phase this will completing as end that through Phase our candidate obtained of last the at of a for year.
slide systems this and very data, you’ll if year, January showed we Xa results a patients. new in corporate deck for Avizorex signs candidate. excited forward. small we’re a the the The going for And filed that of early Phase meaningful Phase of number the see prospects In you about this so Xa product both in improvement why data shows dry-eye product review the
proceed so point from how and chances candidates clinical we here roughly success. commercial our we with important X have to now, our adequate best to with end expect retina that XXXX years from can is ultimately, dry-eye An the of decide their for by product programs data just the and clinical,
especially we continue the our have products pipeline Certainly, globalization with we in U.S., and that plus the Rhopressa to as you efforts in and Japan. when in grow top-line Rocklatan add these Europe
why exciting can You we see accept for future. itself very
of our Rocklatan, for our half data wait year Europe. Mercury we expected X Roclanda this U.S., the the second is Mercury data of for Top-line Outside X in of XXXX.
the Authority calendar Roclanda year. by the hear is approved to hope end this European also by We that of
data, on We Roclanda in the prospects only to but commercial continue on evaluate countries in not well. opportunities will of commercial throughout specific the the also but the based products only Europe region as Mercury our
For our preparing to X in programs are that going commence are for Rhopressa conducted trial be Japan. Japan, we Phase to
past. options about we explore As have talked we partnership continue in the to the
Ireland got of summer. received earlier approval product terrific in this side, that we, Athlone, enter providing the manufacturing year produce as and we’re the to On our facility, U.S. news FDA Rocklatan we in course, we then
not facility. Rhopressa later the this get that helpful to for year out very of same We approval are
But our physician now, on his to let’s the glaucoma in years do Tom to like turn perspectives continue as I’d cover it to ahead. we over franchise landscape, to for Tom? our build
